Latest news for  (OTC:ISPHF) Stock

LGVN: &nbsp;49% &#x7C; <a href="https://www.benzinga.com//node/40002230">Longeveron Announced Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B In Mild Alzheimer's Disease; Study Meets Its Key Objectives To Advance Data Supporting Favorable Benefit/Risk Profile</a>
&nbsp;
PHG: 11% &#x7C; <a href="https://www.benzinga.com//node/40003536">Koninklijke Philips Q2 2024 Adj EPS €0.30 Beats €0.25 Estimate, Sales €4.462B Beat €4.430B Estimate</a>
&nbsp;
LIPO: &nbsp;204% &#x7C; <a href="https://www.benzinga.com//node/40005335">Lipella Pharmaceuticals Commences Phase 2a Trial For LP-310 In Oral Lichen Planus, Enrolls First Patients</a>

Movers

Trading Ideas

LGVN

LIPO

Market-Moving News for July 29th

WIIM

VTVT

vTv Therapeutics shares are trading lower after the company announced the FDA has placed a clinical hold on the cadisegliatin clinical program.

CPTN

Cepton shares are trading higher after the company announced it will be acquired by Koito for $3.17 per share in cash.

William Blair analyst Brian Drab initiates coverage on Modine Manufacturing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOD#NYSE">MOD</a>) with a Outperform rating.

News

Initiation

Analyst Ratings

William Blair Initiates Coverage On Modine Manufacturing with Outperform Rating

Truist Securities analyst Keith Hughes maintains Mohawk Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MHK#NYSE">MHK</a>) with a Buy and raises the price target from $135 to $184.

Price Target

Truist Securities Maintains Buy on Mohawk Industries, Raises Price Target to $184

AMC Entertainment Says This Past Thursday Through Sunday Set Record 2024 Weekend Attendance And Admissions Revenue At Its US Theaters

Full Year 2024&nbsp;Outlook
<ul>
<li>Revenue of&nbsp;$2.5&nbsp;to&nbsp;$2.7 billion</li>
<li>Adjusted EBITDA margin percentage of&nbsp;9.0%&nbsp;to&nbsp;9.6%</li>
<li>Net capital expenditures of&nbsp;$90&nbsp;to&nbsp;$99 million</li>
</ul>

Earnings

Guidance

CTRI

Centuri Initiates 2024 Guidance: Expects Revenue Of $2.5B-$2.7B Vs. $2.877B Est.; Sees Adjusted EBITDA Margin Of 9%-9.6%

Genpact's deep domain knowledge and data expertise enables embecta's vision to make a meaningful impact in the healthcare sector
NEW YORK, July 29, 2024 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4220850-1&amp;h=1902206349&amp;u=https%3A%2F%2Fwww.genpact.com%2F%3Futm_source%3Dggl%26utm_medium%3Dcpc%26utm_campaign%3D4742272061%26gclid%3DCjwKCAjwgdayBhBQEiwAXhMxtmkQxe9rRGSuwgRGZX_ft9X5PLiFgQ_Uha6gpk0TEnRuF4cb_uwCJhoCeGwQAvD_BwE&amp;a=Genpact">Genpact</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/G#NYSE">G</a>), a global professional services and solutions firm delivering outcomes that shape the future, has been working&nbsp;with&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4220850-1&amp;h=1429926164&amp;u=https%3A%2F%2Fwww.embecta.com%2Fen-us%2F&amp;a=embecta">embecta</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMBC#NASDAQ">EMBC</a>), a global diabetes care company, to support its spin-off from Becton Dickinson and Company (BD) and subsequent evolution as an independent leader in the diabetes technology market.

EMBC

Genpact Has Been Working With embecta's To Support Its Spin-Off Into An Independent Diabetes Care Company

Truist Securities analyst Jordan Levy maintains NEXTracker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>) with a Buy and lowers the price target from $70 to $65.

Truist Securities Maintains Buy on NEXTracker, Lowers Price Target to $65

<a href="https://www.globenewswire.com/Tracker?data=Ru8fqsZhLFqPgdBVQWfW8SQo5ubbmzZknojpTn6lBIv59TZPj4INHZgaXIGNfFZF-e28t3dCgVkurVBfvLYL3w==">Cerence Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNC#NASDAQ">CRNC</a>), AI for a world in motion, today announced its collaboration with <a href="https://www.globenewswire.com/Tracker?data=BLdmGdJcBfXzg2p6Op-v10rb7muqVAKoV43V-dIQnW1w7ICaemBNr5W_jTzGeGSe9F_3jL6TJxT6L2SP_29F8HASweTm-M9ZKD2yzBdd-eg=">smart</a>, the new-premium all-electric automobile brand, on the development of AI-powered solutions for smart's next-generation in-car experiences, first available in the <a href="https://www.globenewswire.com/Tracker?data=C3onjwH1m4wAdB4ugZTjXYxlAq6Wu4UWKklCOPG1DBsY_c1xjBkkfND_gHQqAnLMFlVhDxX2Vr7Ul2-lZfTtqiVxvpqovofQH1LUWn6kxCFXa_5cOWiA8ywvQqj6u1EL261GtMFObp65cD2f0VWq4XQlmHPKN3khXJtq-1mZMmaVGbFYUklLrxuG7xto_SvCLrfWo2QcGzDOhpcQ4T2gYw==">Concept #5</a>. smart has always kept a keen focus on emerging technology and remained at the forefront of exploring the best solutions for future urban mobility. In the AI era and with the support of Cerence, smart will create a new generation of future-proof, convenient and sustainable solutions for customers, ensuring an outstanding user experience and setting new industry benchmarks in Europe and other overseas markets outside Mainland China.

Global

CRNC

smart And Cerence Collaborate To Create Next-Gen, Generative AI-Powered In-Car Experience And Setting New Industry Benchmarks In Europe And Other Overseas Markets Outside Mainland China

Lake Street analyst Ryan Meyers initiates coverage on GigaCloud Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCT#NASDAQ">GCT</a>) with a Buy rating and announces Price Target of $50.

Lake Street Initiates Coverage On GigaCloud Tech with Buy Rating, Announces Price Target of $50

Truist Securities analyst Jordan Levy maintains Sunnova Energy Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) with a Buy and raises the price target from $9 to $10.

NOVA

Truist Securities Maintains Buy on Sunnova Energy Intl, Raises Price Target to $10

Asset Entities Inc.&nbsp;("Asset Entities" or "the Company") (NASDAQ:<a href="https://www.benzinga.com/stock/ASST#NASDAQ">ASST</a>), a provider of digital marketing and content delivery services across Discord and other social media platforms, and a Ternary Payment Platform company, today announced that the Company received formal notice (the "Notice") from the Nasdaq Office of General Counsel of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule").

ASST

Asset Entities Regains Compliance With Nasdaq

Centuri Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRI#NYSE">CTRI</a>) reported quarterly earnings of $0.20 per share which missed the analyst consensus estimate of $0.22 by 9.09 percent. The company reported quarterly sales of $672.075 million which missed the analyst consensus estimate of $760.424 million by 11.62 percent. This is a 16.59 percent decrease over sales of $805.779 million the same period last year.

Earnings Misses

Centuri Holdings Q2 2024 Adj EPS $0.20 Misses $0.22 Estimate, Sales $672.075M Miss $760.424M Estimate

Truist Securities analyst Michael Roxland maintains Weyerhaeuser (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WY#NYSE">WY</a>) with a Hold and lowers the price target from $32 to $31.

Truist Securities Maintains Hold on Weyerhaeuser, Lowers Price Target to $31

Wedbush analyst Richard Anderson maintains Healthpeak Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) with a Outperform and raises the price target from $22 to $25.

Wedbush Maintains Outperform on Healthpeak Properties, Raises Price Target to $25

- Baseline data from the AscenD-LB Phase 2a trial in DLB demonstrated that plasma glial fibrillary acidic protein (GFAP) was highly correlated to scores on the CDR-SB; plasma GFAP shown to increase with neurodegenerative progression in DLB – &nbsp;
- AscenD-LB Phase 2a results demonstrated neflamapimod treatment led to significant reduction compared to placebo in plasma GFAP levels in patients with DLB and the effects of neflamapimod on plasma GFAP were associated with improvement in CDR-SB -
BOSTON, July 29, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that plasma biomarker data from the AscenD-LB Phase 2a trial of neflamapimod in patients with dementia with Lewy bodies (DLB), was featured in a poster presentation at the Alzheimer's Association International Conference&#xAE; (AAIC), being held in Philadelphia from July 28-August 1, 2024.

Biotech

General

CRVO

CervoMed Presents On Plasma Biomarker Data, Consistent With Neflamapimod Impacting The Underlying Disease Process In Patients With Dementia With Lewy bodies At AAIC 2024

B of A Securities analyst Derek Hewett maintains Ladder Cap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LADR#NYSE">LADR</a>) with a Neutral and raises the price target from $11 to $13.

LADR

B of A Securities Maintains Neutral on Ladder Cap, Raises Price Target to $13

Centuri Shares Resume Trade

Barclays analyst Carter Gould downgrades Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) from Equal-Weight to Underweight and maintains the price target from $41 to $41.

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

Comments

News

Latest news for (OTC:ISPHF) Stock